

Biovica strengthens the management team

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

Helle Fisker has more than 25 years of experience in commercializing both diagnostics and pharmaceuticals in oncology and other areas. In total, Helle has been involved in launching over 30 treatments and vaccines, and more than 350 medical products worldwide.

Joakim Arwidson has more than 25 years of experience in life science with experience in quality and regulatory affairs from development, production, market introduction and market follow-up in North America, Europe and Asia. Joakim has completed 14 successful 510(k) processes in oncology and theranostics (combining treatment and diagnosis of tumors).

“We are very pleased to strengthen our organization with Helle Fisker and Joakim Arwidson in this exciting phase for Biovica. Their vast experience will be a key part of succeeding with our upcoming launch and the realization of our vision, better outcome of treatment for cancer patients,” said Anders Rylander, CEO of Biovica.

Helle Fisker and Joakim Arwidson will be part of Biovica’s management team.

Contact

Anders Rylander, CEO

Phone: +46-18-444 48 35

E-mail: anders.rylander@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica’s vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica’s shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company’s Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

Image Attachments

[JoakimArwidsonBiovica](#)

[HelleFiskerBiovica](#)

Attachments

[Biovica strengthens the management team](#)



PRESS RELEASE

April 29, 2021